moneyheap
GH · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Guardant Health, Inc. Common Stock (GH) stock moving?
Guardant reported a beat-and-raise Q3 2026 on Nov 5: revenue of $361.0M versus a $350.4M estimate, adjusted EPS of $(0.29) versus $(0.32), and FY2026 revenue guidance lifted to $1.36B-$1.37B against a $1.357B consensus. Despite this, the stock fell about 9% that day, from $168.58 to $153.43, on volume of 4.08M shares, roughly double its recent run-rate. Selling extended on Nov 6 to an intraday low of $136.42 on 5.51M shares before a recovery to $158.79 on Nov 9 and $155.35 on Nov 10. The news items do not state the reason for the post-earnings drop, so the cause is unexplained by the provided sources. Analyst support remains: Piper Sandler kept its Overweight rating and cut its target to $190, still above the latest close. Other items are mixed to supportive. ESMO Open published PRECISION results showing feasibility of pretreatment blood-based profiling in nearly all eligible patients, and Guardant360 Liquid detected alterations in 97% of patients. Shield received a 2026 Prix Galien USA award, and Pennsylvania passed a law removing cost-sharing for colorectal cancer screenings, a tailwind for Shield. Negatives include a USPTO confirmation of all 23 claims of a TwinStrand patent asserted against Guardant. Governance items (Kevin Sayer board appointment, co-CEO PSU grants tied to relative TSR) are neutral. The stock trades about 16% below its Oct 29 close of $185.31.
News behind the analysis
- Guardant Health Announces That ESMO Open Has Published Results From PRECISION; Pretreatment Blood-Based Profiling Was Feasible In Nearly All Eligible Patients; Guardant360 Liquid Detected Genomic Alterations In 97% Of PatientsESMO Open published PRECISION trial results showing pretreatment blood-based profiling was feasible in nearly all eligible patients. Guardant360 Liquid detected genomic alterations in 97% of patients.
- Piper Sandler Maintains Overweight on Guardant Health, Lowers Price Target to $190Piper Sandler kept its Overweight rating on Guardant Health but cut its price target to $190. The shares closed at $155.35 on Nov 10.
- Guardant Health Announces Participation in Upcoming Investor ConferencesGuardant Health will present at the Jefferies Global Healthcare Conference and the Piper Sandler 38th Annual Healthcare Conference. This is a routine corporate update.
- Guardant Health Reports Q3 2026 Financial Results and Raises Full-Year Revenue GuidanceQ3 2026 revenue was $361.0 million, above analyst expectations, and full-year 2026 revenue guidance was raised to $1.36 billion to $1.37 billion. Shares fell after hours despite the beat.
- Guardant Health Raises FY2026 Sales Guidance from $1.340B-$1.360B to $1.360B-$1.370B vs $1.357B EstThe raised FY2026 sales guidance of $1.360B-$1.370B sits above the $1.357B consensus estimate. The change is a modest upward revision at the top end of the range.
- Guardant Health Q3 Adj. EPS $(0.29) Beats $(0.32) Estimate, Sales $360.975M Beat $350.358M EstimateAdjusted EPS of $(0.29) beat the $(0.32) estimate, and sales of $360.975M beat the $350.358M estimate. Both metrics came in ahead of expectations.
- Guardant Health Q3 2026 Earnings Call TranscriptBenzinga published the full transcript of the Q3 2026 earnings call. The transcript provides management commentary on the quarter and outlook.
- TwinStrand Biosciences Announces Confirmation Of U.S. Patent And Trademark Office Regarding Patentability Of All 23 Claims Of U.S. Patent Against Guardant HealthThe USPTO confirmed the patentability of all 23 claims of a TwinStrand Biosciences patent asserted against Guardant Health. This is a negative IP development for Guardant.
- Kevin Sayer Appointed to Guardant Health Board of DirectorsGuardant appointed Kevin Sayer, former Dexcom CEO and current Executive Chairman of Dexcom, to its board. The move adds digital health leadership experience.
About Guardant Health, Inc. Common Stock
Guardant Health is a precision oncology company based in Palo Alto, California. It makes blood tests that detect cancer, help choose treatments and watch for cancer coming back. It is best known for Guardant360, a test that profiles tumors from a blood sample, and Shield, an FDA-approved blood test that screens for colorectal cancer. Revenue has been growing fast (about $982 million in 2025), but the company is still losing money.
How it makes money
Most revenue comes from oncology testing (Guardant360, Reveal and others), which brought in about $219 million, or roughly two-thirds of sales, in Q2 2026. Two other segments make up the rest: services for drugmakers, including companion diagnostics and data (about $61 million in Q2 2026), and screening revenue from Shield tests (about $53 million in Q2 2026, at roughly $800 per test). Screening is the fastest-growing part of the business. Insurers, including Medicare, pay for the tests.
What usually moves GH
- Shield screening test volumes and insurance coverage
- Medicare and private insurer reimbursement rates
- FDA approvals and new companion diagnostic deals
- Cash burn and progress toward profitability
- Competition in blood-based cancer screening